联合应用免疫检查点抑制剂在肝细胞癌合并门静脉癌栓治疗中的研究进展

doi:10.3760/cma.j.cn371439-20240328-00087

摘要/Abstract

摘要：

门静脉癌栓（PVTT）是肝细胞癌（HCC）较为常见的并发症之一，其死亡率较高。多项研究表明，积极处理并实施有效治疗，可以显著改善HCC合并PVTT患者的生命质量及延长生存期。近年来，随着分子生物学与分子免疫学的不断发展，治疗晚期肝癌的方法从单药转向联合治疗，其中，免疫检查点抑制剂与其他全身或局部治疗的联合应用备受关注，这种治疗策略已经在一些大规模临床试验中显示出良好的疗效。随着相关研究不断深入，这种治疗方案将为此类患者带来更多希望和机会。

关键词: 癌, 肝细胞, 门静脉癌栓, 免疫检查点抑制剂, 联合治疗

Abstract:

Portal vein tumor thrombus （PVTT） is one of the common complications of hepatocellular carcinoma （HCC） with a high mortality rate. Several studies have shown that active implementation of effective treatment can significantly improve the quality of life and prolong survival of HCC patients with PVTT. In recent years，with the continuous development of molecular biology and molecular immunology，the treatment of advanced liver cancer has shifted from single agent to combination therapy，among which，the combination of immune checkpoint inhibitors and other systemic or local therapies has attracted much attention. This treatment strategy has shown good efficacy in some large-scale clinical trials. With the deepening of relevant research，it is believed that this treatment scheme will bring more hope and opportunities to such patients.

Key words: Carcinoma, hepatocellular, Portal vein cancer thrombus, Immune checkpoint inhibitors, Combination therapy

莫慧敏, 蔡宇森, 张增瑞, 朱文钿. 联合应用免疫检查点抑制剂在肝细胞癌合并门静脉癌栓治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(8): 520-525.

Mo Huimin, Cai Yusen, Zhang Zengrui, Zhu Wentian. Research progress of the combined application of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Journal of International Oncology, 2024, 51(8): 520-525.

参考文献 46

[1]	Canale M, Foschi FG, Andreone P, et al. Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery[J]. HPB (Oxford), 2022, 24(2): 244-254. DOI: 10.1016/j.hpb.2021.06.421.
[2]	中国医师协会肝癌专业委员会. 中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版)[J]. 中华医学杂志, 2022, 102(4): 243-254. DOI: 10.3760/cma.j.cn112137-20211117-02567.
[3]	Zhang M, Ding QH, Bian CB, et al. Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma[J]. Exp Cell Res, 2023, 426(1): 113563. DOI: 10. 1016/j.yexcr.2023.113563.
[4]	Cheng SQ, Chen MS, Cai JA, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 edition)[J]. Liver Cancer, 2020, 9(1): 28-40. DOI: 10.1159/000503685. pmid: 32071907
[5]	Feng JK, Liu ZH, Fu ZG, et al. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world[J]. Front Oncol, 2022, 12: 954203. DOI: 10.3389/fonc.2022.954203.
[6]	曹佳丽, 熊枝繁, 靳泽, 等. 免疫检查点抑制剂在肝细胞癌治疗中的研究进展[J]. 肿瘤防治研究, 2023, 50(5): 525-530. DOI: 10.3971/j.issn.1000-8578.2023.22.1325.
[7]	周江敏, 周晨阳, 胡新昇, 等. 免疫检查点抑制剂药物在肝细胞癌治疗中的研究进展[J]. 中华实验外科杂志, 2021, 38(10): 2050-2054. DOI: 10.3760/cma.j.cn421213-20210308-00192.
[8]	杜佳家, 黄志勇. 肝细胞癌免疫治疗疗效预测的研究进展[J]. 临床外科杂志, 2023, 31(10): 990-993. DOI: 10.3969/j.issn.1005-6483.2023.10.024.
[9]	El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. pmid: 28434648
[10]	Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6. pmid: 29875066
[11]	王东, 陈玉晓, 董转丽, 等. 中晚期肝癌免疫治疗现状与前景[J]. 现代肿瘤医学, 2022, 30(11): 2065-2068. DOI: 10.3969/j.issn.1672-4992.2022.11.031.
[12]	Yau T, Yoon-Koo K, Tae-You K, et al. Nivolumab(NIVO) + ipilimumab(IPI) combination therapy in patients(pts) with advanced hepatocellular carcinoma(aHCC): results from CheckMate 040[J]. J Clin Oncol, 2019, 37(15_suppl): 4012. DOI: 10.1200/JCO.2019.37.15_suppl.4012.
[13]	Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2021, 39(27): 2991-3001. DOI: 10.1200/JCO.20.03555.
[14]	Khorprasert C, Thonglert K, Alisanant P, et al. Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: feasibility and clinical outcomes[J]. PLoS One, 2021, 16(9): e0257556. DOI: 10.1371/journal.pone.0257556.
[15]	Friedman D, Baird JR, Young KH, et al. Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma[J]. Hepatol Res, 2017, 47(7): 702-714. DOI: 10.1111/hepr.12789. pmid: 27501850
[16]	Hu Y, Zhou M, Tang J, et al. Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus[J]. Clin Cancer Res, 2023, 29(20): 4088-4097. DOI: 10.1158/1078-0432.CCR-22-2592.
[17]	谭钧尹, 原浩, 刘莎, 等. 调强放疗联合免疫检查点抑制剂治疗肝癌并Ⅲ/Ⅳ型门静脉癌栓的近期疗效和安全性分析[J]. 中国实用医药, 2023, 18(13): 1-6. DOI: 10.14163/j.cnki.11-5547/r.2023.13.001.
[18]	Luo F, Li M, Ding J, et al. The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Front Oncol, 2021, 11: 635731. DOI: 10.3389/fonc.2021.635731.
[19]	田津铭, 杨继金. 局部介入联合免疫检查点抑制剂治疗中晚期肝癌研究进展[J]. 国际肿瘤学杂志, 2023, 50(10): 636-640. DOI: 10.3760/cma.j.cn371439-20230428-00121.
[20]	李琪. TACE联合免疫检查点抑制剂治疗合并门静脉癌栓的肝细胞肝癌的疗效和安全性[D]. 泸州: 西南医科大学, 2023. DOI: 10.27215/d.cnki.glzyu.2023.000285.
[21]	Cheu JW, Wong CC. Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors[J]. Hepatology, 2021, 74(4): 2264-2276. DOI: 10.1002/hep.31840.
[22]	Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update[J]. Liver Cancer, 2021, 10(3): 181-223. DOI: 10.1159/000514174. pmid: 34239808
[23]	He P, Ren E, Chen B, et al. A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma[J]. Theranostics, 2022, 12(4): 1769-1782. DOI: 10.7150/thno.68456. pmid: 35198072
[24]	Wu JS, Hong TC, Wu HT, et al. Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan[J]. J Gastrointest Oncol, 2023, 14(2): 849-862. DOI: 10.21037/jgo-22-858.
[25]	Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study[J]. Front Immunol, 2022, 13: 848387. DOI: 10.3389/fimmu.2022.848387.
[26]	Yi C, Chen L, Lin Z, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-pro-grammed cell death-1 in HCC[J]. Hepatology, 2021, 74(5): 2544-2560. DOI: 10.1002/hep.31921.
[27]	Roy A. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2022, 12(6): 1575-1576. DOI: 10.1016/j.jceh.2022.07.003.
[28]	Ren Y, Liu Z, Makamure J, et al. Addition of camrelizumab to transarterial chemoembolization in hepatocellular carcinoma with untreatable progression[J]. Technol Cancer Res Treat, 2022, 21: 15330338221131385. DOI: 10.1177/15330338221131385.
[29]	Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470-2045(21)00252-7.
[30]	Lee SK, Kwon JH, Lee SW, et al. A real-world comparative analysis of atezolizumab plus bevacizumab and transarterial chemoembolization plus radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. Cancers (Basel), 2023, 15(17): 4423. DOI: 10.3390/cancers15174423.
[31]	Chuma M, Uojima H, Hiraoka A, et al. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis[J]. Hepatol Res, 2021, 51(2): 201-215. DOI: 10.1111/hepr.13592. pmid: 33270323
[32]	Nair A, Reece KL, Donoghue MB, et al. FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma[J]. Oncologist, 2021, 26(3): e484-e491. DOI: 10.1002/onco.13566. pmid: 33044793
[33]	Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/JCO.20.00808.
[34]	Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24(12): 1399-1410. DOI:10.1016/S1470-2045(23)00469-2. pmid: 38039993
[35]	Finn RS, Qin SK, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[36]	Jost-Brinkmann F, Demir M, Wree A, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort[J]. Aliment Pharmacol Ther, 2023, 57(11): 1313-1325. DOI: 10.1111/apt.17441.
[37]	宋佳, 胡钦勇. TACE联合靶向、免疫治疗在BCLC B/C期肝细胞癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 550-554. DOI: 10.3760/cma.j.cn371439-20220520-00107.
[38]	Cao F, Zheng J, Luo J, et al. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens[J]. J Cancer Res Clin Oncol, 2021, 147(10): 2993-3002. DOI: 10.1007/s00432-021-03708-1. pmid: 34302208
[39]	Zou X, Xu Q, You R, et al. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features[J]. Cancer Med, 2023, 12(10): 11315-11333. DOI: 10.1002/cam4.5841.
[40]	Li X, Ding X, Liu M, et al. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer Med, 2023, 12(16): 16805-16814. DOI: 10.1002/cam4.6302.
[41]	Fu Y, Peng W, Zhang W, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. J Gastroenterol, 2023, 58(4): 413-424. DOI: 10.1007/s00535-023-01976-x. pmid: 36894804
[42]	Lin ZP, Chen D, Hu XL, et al. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas[J]. Am J Cancer Res, 2023, 13(11): 5455-5465.
[43]	赵莹, 黎可人, 杨艳美, 等. 放射治疗联合免疫检查点抑制剂及仑伐替尼治疗肝细胞癌合并门静脉癌栓的疗效分析[J]. 肝癌电子杂志, 2023, 10(3): 58-63. DOI: 10.3969/j.issn.2095-7815.2023.03.010.
[44]	Li GX, Zhao Y, Li KR, et al. Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: real-world data from a tertiary centre[J]. J Hepatocell Carcinoma, 2023, 10: 2037-2048. DOI: 10.2147/JHC.S432542. pmid: 37965075
[45]	Lin LW, Yan LY, Ke K, et al. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Brachytherapy, 2023, 22(6): 858-871. DOI: 10.1016/j.brachy.2023.06.229.
[46]	Zhang ZH, Hou SN, Yu JZ, et al. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: a propensity-score analysis[J]. Front Oncol, 2022, 12: 1086095. DOI: 10.3389/fonc.2022.1086095.